Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
Decibel Therapeutics (Nasdaq: DBTX) announced that CEO Laurence Reid, Ph.D., will join a fireside chat at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 10:00 a.m. ET in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Decibel Therapeutics (Nasdaq: DBTX) announced that CEO Laurence Reid, Ph.D., will join a fireside chat at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 10:00 a.m. ET in New York City. This event will explore the company's efforts in developing innovative treatments aimed at restoring hearing and balance. A live webcast will be available on the Decibel Therapeutics website, with an archived version accessible for 90 days post-event. Decibel Therapeutics focuses on gene therapies for congenital and acquired hearing disorders.
Details
News Market Reaction – DBTX
The recorded move for DBTX in the trading session of this news was -6.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.
A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200
Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.